Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We inve...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Sci Rep
Huvudupphovsmän: Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853939/
https://ncbi.nlm.nih.gov/pubmed/31723167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-52944-6
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk